Compare Johnson & Johnson (JNJ) vs Marathon Petroleum Corp (MPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Marathon Petroleum Corp — how do they compare? Johnson & Johnson trades at $261.05 (market cap $618.09B), while Marathon Petroleum Corp trades at $461.57 (market cap $130.12B). The key difference: Johnson & Johnson is far larger — about 4.8× Marathon Petroleum Corp's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Marathon Petroleum Corp for 54 Days on average.
| JNJ | MPC | |
|---|---|---|
Market Cap | $618.09B | $130.12B |
Volume | 6,050,983 | 2,749,647 |
Sector | Health | Energy |
52-Week High | $278.43 | $463.34 |
52-Week Low | $186.00 | $162.63 |
Typical Hold Time | 129 Days | 54 Days |
Enterprise Value | $646.37B | $156.64B |
Dividend Yield | 2.09% | 0.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Marathon Petroleum (MPC) trades at $461.79, up 4.42% today, showing strong momentum with three consecutive earnings beats. Technical indicators signal bullish momentum with the stock trading near resistance at $463. Fundamentally, the company maintains solid profitability with 5.57% net margin and 47.9% ROE, though revenue has declined from $177.5B in 2022 to $132.7B in 2025. Analyst consensus remains strongly bullish with 25 buy ratings and a $420.30 price target.
MPC presents a compelling value opportunity with attractive valuation multiples (P/E 16.07, P/S 0.9) and strong earnings momentum. Key risks include potential diesel export restrictions, declining revenue trends, and elevated debt levels. The stock's current price above consensus target suggests near-term caution despite positive technical and fundamental momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →
